Paratek

Quote

anonymous said:
Nobody is performing well, unless you are one of the few that have off-label business.
Promised Wall Street 10-13M in sales for 2019. Delivered only 3M through 2Q. Everyone here knows that 3Q is not looking good, thus the sense of panic and desperation. 10-13M this year ain’t happening.
No hospitals are adding Nuzyra to formulary. Xerava is getting P&T approvals.
How much longer will the board allow management to lose 30M+ each quarter?
Click to expand...
mycobacteria (NTM) OMG!
 


Anyone know the salary for institutional sales rep? These are Paratek jobs, not contract Amplity jobs, right? I’d like to get out of primary care and get some specialty experience
 














All of these comments are spot on. Horrible work environment, terrible marketing, cocky, arrogant, micro-management. Amplity should be embarrassed for taking this mess on as a client.
 










The earnings call sure painted a rosy picture. We only lost 32 million! The high formulary rejection rate and the fact that almost no hospitals have added it to formulary or protocols was not discussed.
How are we supposed to get CABP business if hospitals have rejected Nuzyra in favor of the less expensive and efficacious Xerava, Xenleta, tiggy, and moxi? How is it going to get started for CABP if it’s not stocked because it’s not on formulary?
Apparently we are expected to do 4 million this quarter? How? The answer is to recertify and make more calls!!!!
(And by the way, it’s pronounced “in·vuhn·taw·ree” not “in•ven•tree”)
 


anonymous said:
The earnings call sure painted a rosy picture. We only lost 32 million! The high formulary rejection rate and the fact that almost no hospitals have added it to formulary or protocols was not discussed.
How are we supposed to get CABP business if hospitals have rejected Nuzyra in favor of the less expensive and efficacious Xerava, Xenleta, tiggy, and moxi? How is it going to get started for CABP if it’s not stocked because it’s not on formulary?
Apparently we are expected to do 4 million this quarter? How? The answer is to recertify and make more calls!!!!
(And by the way, it’s pronounced “in·vuhn·taw·ree” not “in•ven•tree”)
Click to expand...
NTM
 


Have a phone screen with hr Monday at 2 for this company but now I’m feeling like canceling that......anyone actually work there that’s been replying to the forum? Of course everyone that left is going to leave bad comments. Thanks in advance.
 


anonymous said:
The earnings call sure painted a rosy picture. We only lost 32 million! The high formulary rejection rate and the fact that almost no hospitals have added it to formulary or protocols was not discussed.
How are we supposed to get CABP business if hospitals have rejected Nuzyra in favor of the less expensive and efficacious Xerava, Xenleta, tiggy, and moxi? How is it going to get started for CABP if it’s not stocked because it’s not on formulary?
Apparently we are expected to do 4 million this quarter? How? The answer is to recertify and make more calls!!!!
(And by the way, it’s pronounced “in·vuhn·taw·ree” not “in•ven•tree”)
Click to expand...

Did Loh write that last post? Lol

“Paratek says its new antibiotic Nuzyra treats pneumonia and skin infections with fewer toxic side effects, but it's been a tough sell at many hospitals, where budgets are tight and federal Medicare reimbursements for antibiotics are low.

"Payers and hospitals have said, you know, 'we have our generics, we need to control our costs … we'll just go ahead with the older antibiotics that we have here today.' They're telling us they don't want our innovation," Loh said.”

https://www.cbsnews.com/news/drug-r...tics-needed-high-cost-preventing-development/
 


anonymous said:
The earnings call sure painted a rosy picture. We only lost 32 million! The high formulary rejection rate and the fact that almost no hospitals have added it to formulary or protocols was not discussed.
How are we supposed to get CABP business if hospitals have rejected Nuzyra in favor of the less expensive and efficacious Xerava, Xenleta, tiggy, and moxi? How is it going to get started for CABP if it’s not stocked because it’s not on formulary?
Apparently we are expected to do 4 million this quarter? How? The answer is to recertify and make more calls!!!!
(And by the way, it’s pronounced “in·vuhn·taw·ree” not “in•ven•tree”)
Click to expand...

https://www.cbsnews.com/news/drug-r...tics-needed-high-cost-preventing-development/

“Paratek says its new antibiotic Nuzyra treats pneumonia and skin infections with fewer toxic side effects, but it's been a tough sell at many hospitals, where budgets are tight and federal Medicare reimbursements for antibiotics are low.

"Payers and hospitals have said, you know, 'we have our generics, we need to control our costs … we'll just go ahead with the older antibiotics that we have here today.' They're telling us they don't want our innovation," Loh said.”

Maybe Loh wrote the previous post!!!
 


anonymous said:
Have a phone screen with hr Monday at 2 for this company but now I’m feeling like canceling that......anyone actually work there that’s been replying to the forum? Of course everyone that left is going to leave bad comments. Thanks in advance.
Click to expand...
Ask recruiter about all the role playing.
we had a 2 1/2 hour conference call on messaging and had to verbalize the message on call. Funny stuff!
 





Write your reply...
Top Bottom
Back
Quote